Replies to post #237438 on Biotech Values

[Biowatch]

Antibiotics may be another case of losing a battle when there is insufficient funding and an ever evolving foe, much as is the case with vaccines, the current pandemic being an exception to the rule.

https://www.newyorker.com/tech/annals-of-technology/phage-killer-viral-dark-matter

Some people are investigating bacteriophages as another approach to fight bacteria.

[DewDiligence]

CFRX has a lingering credibility issue vis-à-vis reporting of clinical results (#msg-145924472)—in addition to a dubious business model (#msg-162639512). Still, there’s an unmet medical need for better antibiotics, so I hope the company does well.